Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

2013598 citationsJournal Articlebronze Open Access

Authors

Alexander T Cohen · King's College Hospital

Theodore E. Spiro · Bayer (United States)

Harry R. Büller · Academic Medical Center

Lloyd Haskell · Janssen (United States)

Dayi Hu · Peking University

Russell D. Hull · Foothills Medical Centre

Alexandre Mebazaa ·

Abstract

In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thromboprophylaxis. Extended-duration rivaroxaban reduced the risk of venous thromboembolism. Rivaroxaban was associated with an increased risk of bleeding. (Funded by Bayer HealthCare Pharmaceuticals and Janssen Research and Development; MAGELLAN ClinicalTrials.gov number, NCT00571649.).

Topics & Keywords

Venous Thromboembolism Diagnosis and Management Atrial Fibrillation Management and Outcomes Acute Myocardial Infarction Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 368, Issue 6, pp. 513-523

DOI: 10.1056/nejmoa1111096

Field-Weighted Citation Impact: 49.48